HC Wainwright Has Positive Estimate for COYA FY2024 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Stock analysts at HC Wainwright boosted their FY2024 EPS estimates for shares of Coya Therapeutics in a report released on Monday, November 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($1.13) per share for the year, up from their previous estimate of ($1.38). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.68) EPS.

Separately, Chardan Capital reissued a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, November 7th.

Coya Therapeutics Stock Performance

Shares of Coya Therapeutics stock opened at $6.32 on Thursday. The firm’s 50-day simple moving average is $7.12 and its 200-day simple moving average is $7.00. Coya Therapeutics has a twelve month low of $4.75 and a twelve month high of $10.69. The firm has a market cap of $105.61 million, a P/E ratio of -9.72 and a beta of 0.46.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.15.

Insider Activity at Coya Therapeutics

In related news, CEO Arun Swaminathan bought 5,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was bought at an average cost of $7.34 per share, with a total value of $36,700.00. Following the completion of the purchase, the chief executive officer now owns 5,000 shares in the company, valued at approximately $36,700. The trade was a ? increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders bought 9,510 shares of company stock valued at $69,615 in the last ninety days. Insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Coya Therapeutics

A number of institutional investors have recently modified their holdings of COYA. Gilbert & Cook Inc. bought a new stake in shares of Coya Therapeutics during the second quarter worth approximately $61,000. Renaissance Technologies LLC bought a new stake in shares of Coya Therapeutics during the second quarter worth approximately $101,000. GHP Investment Advisors Inc. bought a new stake in shares of Coya Therapeutics during the third quarter worth approximately $169,000. Finally, Vanguard Group Inc. raised its stake in shares of Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after buying an additional 750,338 shares during the last quarter. 39.75% of the stock is owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.